Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGA4 | P13612 | 17/20 | 0.44 |
| ▸ | ITGB1 | P05556 | 16/20 | 0.44 |
| ▸ | ITGB7 | P26010 | 11/20 | 0.44 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.40 |
| ▸ | CPA1 | P15085 | 1/20 | 0.40 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.40 |
| ▸ | GPR34 | Q9UPC5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3977291 | 0.94 | PYGL (0.41) | ITGA4ITGB1ITGB7 | |
| SCHEMBL5926509 | 0.94 | ITGA4 (0.44) | ITGA4ITGB1ITGB7MMEACE | |
| SCHEMBL3998771 | 0.92 | ITGA4 (0.42) | ITGA4ITGB1ITGB7MMEACE | |
| SCHEMBL5926298 | 0.89 | ITGA4 (0.47) | ITGA4ITGB1ITGB7GPR34 | |
| SCHEMBL5926807 | 0.87 | ITGA4 (0.44) | ITGA4ITGB1ITGB7GPR34 | |
| SCHEMBL5926997 | 0.87 | ITGA4 (0.44) | ITGA4ITGB1ITGB7GPR34 | |
| SCHEMBL5926204 | 0.87 | ITGA4 (0.44) | ITGA4ITGB1ITGB7GPR34 | |
| SCHEMBL4255107 | 0.86 | PTGER4 (0.41) | — | |
| SCHEMBL5926933 | 0.85 | ITGA4 (0.46) | ITGA4ITGB1ITGB7 | |
| SCHEMBL5927430 | 0.85 | GPR34 (0.47) | ITGA4ITGB1ITGB7GPR34 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501538-B2 | Aryl and heteroaryl compounds, compositions and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501538-B2 | Aryl and heteroaryl compounds, compositions and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-7501538-B2 | Aryl and heteroaryl compounds, compositions and methods of use | TRANSTECH PHARMA, INC. (US) | 2009-03-10 | — | — | US | disclosed |
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | VTVX HOLDINGS I LLC | 2005-03-03 | — | — | US | disclosed |
| WO-2005014532-A1 | ARYL AND HETEROARYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE | TRANSTECH PHARMA, INC. (US) | 2005-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050049310-A1 | Aryl and heteroaryl compounds, compositions and methods of use | EPOR, HBG2, CYP2F1 | ITGA4 1777/4885ITGB1 1520/4885ITGB7 1082/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.